| Followers | 280 |
| Posts | 1175 |
| Boards Moderated | 0 |
| Alias Born | 10/04/2020 |
Friday, October 22, 2021 11:52:08 AM
The Implications Of Dr. Koos Hiring Biotech Research Group
I predict when Biotech Research Group completes the independent Valuation of RGBP's I.P. and Regulatory related matters on 11/15/21, within 4 weeks Dr. Koos is going to drop his first PR announcing either a Merger/Acquisition OR the NR2F6 Patent has entered Clinical Trials for treating Pancreatic & Colon Cancer by mRNA Vaccine.
This is my personal opinion but one that makes sense based on him hiring that firm which cost him $25,000.00. No industry professional/CEO would shell out that kind of cash unless they have a very clear comprehension of the traction it's going to produce moving toward acquisition or commercialization.
This is the most strategic move Koos made so far and EVERYONE here needs to give him a round of applause for the extraordinary speed in which he brought this Company Pink Current including the updates he's executed to revive RGBP's Patents since he returned as CEO earlier this year AND him dropping on the average of 3 SEC Filings PER WEEK dating back to March this year. To date that's MORE than 30 SEC filings; totally unheard of on the OTC.
If this goes in the direction of a Merger/Acquisition I strongly believe Eli Lilly is the suitor due to their prior collaboration on the same molecule.
This man is OWED A LOT of credit!
Again this is my personal Opinion only.
Feedback welcome from all...
Be well and prosper...
I predict when Biotech Research Group completes the independent Valuation of RGBP's I.P. and Regulatory related matters on 11/15/21, within 4 weeks Dr. Koos is going to drop his first PR announcing either a Merger/Acquisition OR the NR2F6 Patent has entered Clinical Trials for treating Pancreatic & Colon Cancer by mRNA Vaccine.
This is my personal opinion but one that makes sense based on him hiring that firm which cost him $25,000.00. No industry professional/CEO would shell out that kind of cash unless they have a very clear comprehension of the traction it's going to produce moving toward acquisition or commercialization.
This is the most strategic move Koos made so far and EVERYONE here needs to give him a round of applause for the extraordinary speed in which he brought this Company Pink Current including the updates he's executed to revive RGBP's Patents since he returned as CEO earlier this year AND him dropping on the average of 3 SEC Filings PER WEEK dating back to March this year. To date that's MORE than 30 SEC filings; totally unheard of on the OTC.
If this goes in the direction of a Merger/Acquisition I strongly believe Eli Lilly is the suitor due to their prior collaboration on the same molecule.
This man is OWED A LOT of credit!
Again this is my personal Opinion only.
Feedback welcome from all...
Be well and prosper...
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
